The Patent Finder
GE

Genzyme Corporation

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

307 patents currently held

44 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
58
Ending by 2030
Jan 2027
Next term end
188
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances US 9,650,412
Cited by 68 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Ends Mar 2034 · High confidence
Also notable
FC Containing Polypeptides with Altered Glycosylation and Reduced Effector Function US 9,790,268
Cited by 40 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Ends Mar 2034 · Medium confidence
Also notable
Amorphous and a Crystalline Form of Genz 112638 Hemitartrate as Inhibitor of Glucosylceramide Synthase US 11,458,119
Cited by 11 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2030.
Ends Nov 2030 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 4 fees due Dec 11 to 30, 2026 · next Dec 11
  • 3 fees due Jan 9 to 11, 2027 · next Jan 9
  • 5 fees due Feb 4 to 25, 2027 · next Feb 4
  • 3 fees due Mar 8 to 22, 2027 · next Mar 8
  • 6 fees due Apr 1 to 30, 2027 · next Apr 1
  • 5 fees due May 3 to 14, 2027 · next May 3
  • 8 fees due Jun 3 to 26, 2027 · next Jun 3
  • 4 fees due Jul 2 to 30, 2027 · next Jul 2
  • 8 fees due Aug 13 to 27, 2027 · next Aug 13
  • 3 fees due Sep 5 to 30, 2027 · next Sep 5
  • 3 fees due Oct 2 to 28, 2027 · next Oct 2
  • 4 fees due Nov 3 to 12, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,455,248Powder Delivery Device
In force
 · High confidence
In forceHigh confidence
US 8,926,967Intraventricular Enzyme Delivery for Lysosomal Storage Diseases
In force
 · High confidence
In forceHigh confidence
US 10,080,783Intraventricular Enzyme Delivery for Lysosomal Storage Diseases
In force
 · High confidence
In forceHigh confidence
US 11,253,485Slow Intraventricular Delivery
In force
 · High confidence
In forceHigh confidence
US 8,062,282Methods and Apparatus for Temporarily Occluding Body Openings
In force
 · High confidence
In forceHigh confidence
US 9,890,394Gene Therapy for Amyotrophic Lateral Sclerosis and Other Spinal Cord Disorders
In force
 · High confidence
In forceHigh confidence
US 10,920,245Gene Therapy for Amyotrophic Lateral Sclerosis and Other Spinal Cord Disorders
In force
 · High confidence
In forceHigh confidence
US 7,815,623Stepped Cannula
In force
 · High confidence
In forceHigh confidence
US 11,554,161Gene Therapy for Amyotrophic Lateral Sclerosis and Other Spinal Cord Disorders
In force
 · High confidence
In forceHigh confidence
US 8,163,926Process for the Synthesis of Piperidinyl Sulphonate Esters
In force
 · High confidence
In forceHigh confidence
10 of 307 patents shown.
Pro members see all 307.
Pro members: see all 307 patents
Also on record, not counted in the 307: 44 patents in force now held by others · 292 patents ended · 161 applications pending · 408 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited